NEPHROCHECK Biomarkers TIMP-2 and IGFBP7 Included in the ERAS “Guidelines for ...
Medical Health News,
MARCY L’ÉTOILE, France--()--Regulatory News: The biomarkers (TIMP- and IGFBP) that indicate kidney stress in advance of acute…
MARCY L’ÉTOILE, France--()--Regulatory News: The biomarkers (TIMP- and IGFBP) that indicate kidney stress in advance of acute…
@media screen and (min-width:1201px){.sfufe5cd90542c31d3{display:block}}@media screen and (min-width:993px) and (max-width:1200px…
Regulatory News: The NEPHROCHECK ® Test biomarkers (TIMP-2 and IGFBP7) that indicate kidney stress in advance of acute kidney…
MARCY L’ÉTOILE, France --(BUSINESS WIRE)-- Regulatory News: The NEPHROCHECK ® Test biomarkers (TIMP-2 and IGFBP7) that indicate…
NEPHROCHECK Biomarkers TIMP-2 and IGFBP7 Included in the ERAS "Guidelines for Perioperative Care in Cardiac Surgery" MARCY L'ÉTOI…
MARCY L’ÉTOILE, France--( BUSINESS WIRE )--Regulatory News: The NEPHROCHECK ® Test biomarkers (TIMP-2 and IGFBP7) that indicate…
Regulatory News: bioMérieux (Paris:BIM): The biomarkers in the, an FDA-cleared and CE-marked urine test that indicates kidney…
MARCY L’ÉTOILE, France
MARCY L'ÉTOILE, France
MARCY L’ÉTOILE, France
Information contained on this page is provided by an independent third-party content provider.
Information contained on this page is provided by an independent third-party content provider.
/PRNewswire/ -- Ortho Clinical Diagnostics, a global leader of in vitro diagnostics, welcomes and supports today's inclusion of…
Recommends Use of NEPHROCHECK Biomarkers TIMP-2 x IGFP-7 to Assess Risk of Acute Kidney Injury PR Newswire RARITAN, N.J., May 1…
/PRNewswire/ --, a global leader of in vitro diagnostics, welcomes and supports today's inclusion of the biomarkers in the, an…
Supports ERAS® Cardiac Surgery Consensus Statement of Best Practices to Enhance Recovery After Heart Surgery RARITAN, N.J., May…
Information contained on this page is provided by an independent third-party content provider.
Information contained on this page is provided by an independent third-party content provider.
SAN DIEGO, Oct. 31, 2017 /PRNewswire/ --., developer of biomarkers for better healthcare, today previewed several presentations…
SAN DIEGO, Oct. 31, 2017 /PRNewswire/ -- Astute Medical, Inc., developer of biomarkers for better healthcare, today previewed…
SAN DIEGO, Oct. 31, 2017 /PRNewswire/ -- Astute Medical, Inc., developer of biomarkers for better healthcare, today previewed…
SOURCE Astute Medical, Inc. Randomized Control Trial Reports 66 Percent Reduction In Moderate To Severe AKI; $2,000 Per Patient…
SOURCE Astute Medical, Inc. Randomized Control Trial Reports 66 Percent Reduction In Moderate To Severe AKI; $2,000 Per Patient…
SOURCE Astute Medical, Inc. Randomized Control Trial Reports 66 Percent Reduction In Moderate To Severe AKI; $2,000 Per Patient…
Information contained on this page is provided by an independent third-party content provider.
SOURCE Astute Medical, Inc. Randomized Control Trial Reports 66 Percent Reduction In Moderate To Severe AKI; $2,000 Per Patient…
SOURCE Astute Medical, Inc. Randomized Control Trial Reports 66 Percent Reduction In Moderate To Severe AKI; $2,000 Per Patient…
SOURCE Astute Medical, Inc. Randomized Control Trial Reports 66 Percent Reduction In Moderate To Severe AKI; $2,000 Per Patient…
SOURCE Astute Medical, Inc. Randomized Control Trial Reports 66 Percent Reduction In Moderate To Severe AKI; $2,000 Per Patient…
SOURCE Astute Medical, Inc. Randomized Control Trial Reports 66 Percent Reduction In Moderate To Severe AKI; $2,000 Per Patient…
SOURCE Astute Medical, Inc. Randomized Control Trial Reports 66 Percent Reduction In Moderate To Severe AKI; $2,000 Per Patient…
SOURCE Astute Medical, Inc. Randomized Control Trial Reports 66 Percent Reduction In Moderate To Severe AKI; $2,000 Per Patient…
SOURCE Astute Medical, Inc. Randomized Control Trial Reports 66 Percent Reduction In Moderate To Severe AKI; $2,000 Per Patient…
SOURCE Astute Medical, Inc. Randomized Control Trial Reports 66 Percent Reduction In Moderate To Severe AKI; $2,000 Per Patient…
SOURCE Astute Medical, Inc. Randomized Control Trial Reports 66 Percent Reduction In Moderate To Severe AKI; $2,000 Per Patient…
SOURCE Astute Medical, Inc. Randomized Control Trial Reports 66 Percent Reduction In Moderate To Severe AKI; $2,000 Per Patient…
SOURCE Astute Medical, Inc. Randomized Control Trial Reports 66 Percent Reduction In Moderate To Severe AKI; $2,000 Per Patient…
SOURCE Astute Medical, Inc. Randomized Control Trial Reports 66 Percent Reduction In Moderate To Severe AKI; $2,000 Per Patient…
SOURCE Astute Medical, Inc. Randomized Control Trial Reports 66 Percent Reduction In Moderate To Severe AKI; $2,000 Per Patient…
SOURCE Astute Medical, Inc. Randomized Control Trial Reports 66 Percent Reduction In Moderate To Severe AKI; $2,000 Per Patient…
SOURCE Astute Medical, Inc. Randomized Control Trial Reports 66 Percent Reduction In Moderate To Severe AKI; $2,000 Per Patient…
SOURCE Astute Medical, Inc. Randomized Control Trial Reports 66 Percent Reduction In Moderate To Severe AKI; $2,000 Per Patient…
SOURCE Astute Medical, Inc. Randomized Control Trial Reports 66 Percent Reduction In Moderate To Severe AKI; $2,000 Per Patient…
SOURCE Astute Medical, Inc. Randomized Control Trial Reports 66 Percent Reduction In Moderate To Severe AKI; $2,000 Per Patient…
SOURCE Astute Medical, Inc. Randomized Control Trial Reports 66 Percent Reduction In Moderate To Severe AKI; $2,000 Per Patient…
SOURCE Astute Medical, Inc. Randomized Control Trial Reports 66 Percent Reduction In Moderate To Severe AKI; $2,000 Per Patient…
SOURCE Astute Medical, Inc. Randomized Control Trial Reports 66 Percent Reduction In Moderate To Severe AKI; $2,000 Per Patient…
SOURCE Astute Medical, Inc. Randomized Control Trial Reports 66 Percent Reduction In Moderate To Severe AKI; $2,000 Per Patient…
Information contained on this page is provided by an independent third-party content provider.
SOURCE Astute Medical, Inc. Randomized Control Trial Reports 66 Percent Reduction In Moderate To Severe AKI; $2,000 Per Patient…
SOURCE Astute Medical, Inc. Randomized Control Trial Reports 66 Percent Reduction In Moderate To Severe AKI; $2,000 Per Patient…
SOURCE Astute Medical, Inc. Randomized Control Trial Reports 66 Percent Reduction In Moderate To Severe AKI; $2,000 Per Patient…
SOURCE Astute Medical, Inc. Randomized Control Trial Reports 66 Percent Reduction In Moderate To Severe AKI; $2,000 Per Patient…
SOURCE Astute Medical, Inc. Randomized Control Trial Reports 66 Percent Reduction In Moderate To Severe AKI; $2,000 Per Patient…
SOURCE Astute Medical, Inc. Randomized Control Trial Reports 66 Percent Reduction In Moderate To Severe AKI; $2,000 Per Patient…
SOURCE Astute Medical, Inc. Randomized Control Trial Reports 66 Percent Reduction In Moderate To Severe AKI; $2,000 Per Patient…
SOURCE Astute Medical, Inc. Randomized Control Trial Reports 66 Percent Reduction In Moderate To Severe AKI; $2,000 Per Patient…
SOURCE Astute Medical, Inc. Randomized Control Trial Reports 66 Percent Reduction In Moderate To Severe AKI; $2,000 Per Patient…
SOURCE Astute Medical, Inc. Randomized Control Trial Reports 66 Percent Reduction In Moderate To Severe AKI; $2,000 Per Patient…
SOURCE Astute Medical, Inc. Randomized Control Trial Reports 66 Percent Reduction In Moderate To Severe AKI; $2,000 Per Patient…
SOURCE Astute Medical, Inc. Randomized Control Trial Reports 66 Percent Reduction In Moderate To Severe AKI; $2,000 Per Patient…
SOURCE Astute Medical, Inc. Randomized Control Trial Reports 66 Percent Reduction In Moderate To Severe AKI; $2,000 Per Patient…
SOURCE Astute Medical, Inc. Randomized Control Trial Reports 66 Percent Reduction In Moderate To Severe AKI; $2,000 Per Patient…
SOURCE Astute Medical, Inc. Randomized Control Trial Reports 66 Percent Reduction In Moderate To Severe AKI; $2,000 Per Patient…
SOURCE Astute Medical, Inc. Randomized Control Trial Reports 66 Percent Reduction In Moderate To Severe AKI; $2,000 Per Patient…
SAN DIEGO, Sept. 5, 2017 /PRNewswire/ -- Astute Medical, Inc., developer of biomarkers for better healthcare, said a newly…
SAN DIEGO "Interestingly, it appears the prediction of imminent AKI at the very early stage, followed by optimal fluid…
SAN DIEGO, Sept. 5, 2017 /PRNewswire/ -- Astute Medical, Inc., developer of biomarkers for better healthcare, said a showing…
SAN DIEGO, Sept. 5, 2017 /PRNewswire/ -- Astute Medical, Inc., developer of biomarkers for better healthcare, said a newly…
Randomized Control Trial Reports 66 Percent Reduction In Moderate To Severe AKI; $2,000 Per Patient Savings SAN DIEGO, Sept.
SAN DIEGO, Sept. 5, 2017 /PRNewswire/ -- Astute Medical, Inc., developer of biomarkers for better healthcare, said a newly…
SOURCE Astute Medical, Inc. SAN DIEGO AKI has frustrated physicians for years because until recently there's been no reliable…
SOURCE Astute Medical, Inc. SAN DIEGO AKI has frustrated physicians for years because until recently there's been no reliable…
SOURCE Astute Medical, Inc. SAN DIEGO AKI has frustrated physicians for years because until recently there's been no reliable…
SOURCE Astute Medical, Inc. SAN DIEGO AKI has frustrated physicians for years because until recently there's been no reliable…
SOURCE Astute Medical, Inc. SAN DIEGO AKI has frustrated physicians for years because until recently there's been no reliable…
SOURCE Astute Medical, Inc. SAN DIEGO AKI has frustrated physicians for years because until recently there's been no reliable…
SOURCE Astute Medical, Inc. SAN DIEGO AKI has frustrated physicians for years because until recently there's been no reliable…
SOURCE Astute Medical, Inc. SAN DIEGO AKI has frustrated physicians for years because until recently there's been no reliable…
SOURCE Astute Medical, Inc. SAN DIEGO AKI has frustrated physicians for years because until recently there's been no reliable…
SOURCE Astute Medical, Inc. SAN DIEGO AKI has frustrated physicians for years because until recently there's been no reliable…
Information contained on this page is provided by an independent third-party content provider.
SOURCE Astute Medical, Inc. SAN DIEGO AKI has frustrated physicians for years because until recently there's been no reliable…
SOURCE Astute Medical, Inc. SAN DIEGO AKI has frustrated physicians for years because until recently there's been no reliable…
SOURCE Astute Medical, Inc. SAN DIEGO AKI has frustrated physicians for years because until recently there's been no reliable…
SOURCE Astute Medical, Inc. SAN DIEGO AKI has frustrated physicians for years because until recently there's been no reliable…
SOURCE Astute Medical, Inc. SAN DIEGO AKI has frustrated physicians for years because until recently there's been no reliable…
SOURCE Astute Medical, Inc. SAN DIEGO AKI has frustrated physicians for years because until recently there's been no reliable…
SOURCE Astute Medical, Inc. SAN DIEGO AKI has frustrated physicians for years because until recently there's been no reliable…
SOURCE Astute Medical, Inc. SAN DIEGO AKI has frustrated physicians for years because until recently there's been no reliable…
SOURCE Astute Medical, Inc. SAN DIEGO AKI has frustrated physicians for years because until recently there's been no reliable…
SOURCE Astute Medical, Inc. SAN DIEGO AKI has frustrated physicians for years because until recently there's been no reliable…
SOURCE Astute Medical, Inc. SAN DIEGO AKI has frustrated physicians for years because until recently there's been no reliable…
SOURCE Astute Medical, Inc. SAN DIEGO AKI has frustrated physicians for years because until recently there's been no reliable…